We are live on ! Find out more
HVC

Healthcare Value Capital Portfolio holdings

AUM $50.7M
1-Year Est. Return 24.72%
This Fund
S&P 500
This Quarter Est. Return
+3.61%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$50.2M
AUM Growth
+$5.29M
Cap. Flow
+$6.82M
Cap. Flow %
13.6%
Top 10 Hldgs %
67.92%
Holding
24
New
2
Increased
8
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$1.63M
2
MRK icon
Merck
MRK
+$1.42M
3
AZN icon
AstraZeneca
AZN
+$1.37M
4
MDXG icon
MiMedx Group
MDXG
+$1.35M
5
ALKS icon
Alkermes
ALKS
+$1.11M

Top Sells

Rank Stock Value
1
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$1.3M

Sector Composition

Rank Sector Weight
1 Healthcare 89.02%
2 Miscellaneous 7.86%
3 Consumer Staples 3.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
1
Gilead Sciences
GILD
$185B
$5.17M 10.29%
75,000
– –
GSK icon
2
GSK
GSK
$101B
$3.98M 7.93%
80,000
– –
PFE icon
3
Pfizer
PFE
$160B
$3.92M 7.8%
100,000
– –
ALKS icon
4
Alkermes
ALKS
$8.21B
$3.68M 7.33%
150,000
+50,000
+50% +$1.11M
BMY icon
5
Bristol-Myers Squibb
BMY
$137B
$3.34M 6.66%
50,000
+25,000
+100% +$1.63M
MRK icon
6
Merck
MRK
$369B
$3.11M 6.2%
40,000
+19,040
+91% +$1.42M
AZN icon
7
AstraZeneca
AZN
$255B
$3M 5.97%
25,000
+12,500
+100% +$1.37M
CLVS
8
DELISTED
Clovis Oncology, Inc.
CLVS
$2.9M 5.78%
500,000
+50,000
+11% +$293K
IRWD icon
9
Ironwood Pharmaceuticals
IRWD
$702M
$2.57M 5.13%
200,000
– –
AMYT
10
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$2.43M 4.83%
200,000
+44,445
+29% +$552K
COLL icon
11
Collegium Pharmaceutical
COLL
$819M
$2.36M 4.71%
100,000
– –
ATRS
12
DELISTED
Antares Pharma, Inc.
ATRS
$2.18M 4.34%
500,000
– –
TYME
13
DELISTED
Tyme Technologies, Inc. Common Stock
TYME
$1.89M 3.77%
1,500,000
– –
YARW
14
Yarrow Bioscience
YARW
$104M
$1.58M 3.15%
500
+56
+13% +$222K
GNLN icon
15
Greenlane Holdings
GNLN
$1.95M
– –
0
– –
MDXG icon
16
MiMedx Group
MDXG
$659M
$1.56M 3.12%
+125,000
New +$1.35M
SQQQ icon
17
CALL
ProShares UltraPro Short QQQ
SQQQ
$1.79B
$914K 1.82%
+800
New +$1.1M
SPXU icon
18
CALL
ProShares UltraPro Short S&P 500
SPXU
$384M
$911K 1.82%
2,500
-2,500
-50% -$1M
AMRN
19
CALL
Amarin Corp
AMRN
$299M
$876K 1.75%
10,000
-5,000
-33% -$491K
IRWD icon
20
CALL
Ironwood Pharmaceuticals
IRWD
$702M
$644K 1.28%
50,000
– –
VIXY icon
21
CALL
ProShares VIX Short-Term Futures ETF
VIXY
$212M
$602K 1.2%
1,250
– –
ADMS
22
DELISTED
Adamas Pharmaceuticals
ADMS
$528K 1.05%
100,000
– –
GMDA
23
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$481K 0.96%
75,000
+25,000
+50% +$172K
AUPH icon
24
Aurinia Pharmaceuticals
AUPH
$2.19B
– –
-100,000
Closed -$1.3M

Similar funds

C
Castlelake Minneapolis, Minnesota $48.5M AUM 87.77% 1-Year Est. Return
CC
Cedar Capital Barrington, Illinois $54.9M AUM 33.3% 1-Year Est. Return
FCOI
FirstMark Capital OF II New York $44.1M AUM 18.15% 1-Year Est. Return
FCOI
FirstMark Capital OF I New York $43.1M AUM 6.31% 1-Year Est. Return
BI
BCBSM Inc Eagan, Minnesota $42.4M AUM 0.4% 1-Year Est. Return
KC
Kelso & Company New York $42.3M AUM
SCIM
Spring Creek Investment Management Philadelphia, Pennsylvania $42.3M AUM 31.86% 1-Year Est. Return
MCP
Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return

Healthcare Value Capital's Q2 2021 Portfolio in Review

As of Q2 2021, Healthcare Value Capital held 24 positions worth $50.2M, up 12% from $44.9M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Healthcare Value Capital deployed $6.82M of net new capital in Q2 2021, opening 2 new positions and adding to 8 existing holdings. Its largest new stake was MiMedx Group: 125,000 shares worth $1.56M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 84% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the most notable exit was Aurinia Pharmaceuticals, an estimated $1.3M sold.

  • Healthcare Value Capital's largest Q2 2021 buy was MiMedx Group: 125,000 shares worth $1.56M.
  • Healthcare Value Capital added most to Bristol-Myers Squibb in Q2 2021, an estimated $1.63M increase.
  • Healthcare Value Capital fully exited Aurinia Pharmaceuticals in Q2 2021, selling an estimated $1.3M.
  • Healthcare Value Capital's ten largest holdings make up 68% of its $50.2M portfolio in Q2 2021.
  • Healthcare Value Capital opened 2 new positions and closed 1 in Q2 2021.
  • Healthcare Value Capital's portfolio value rose 12% quarter-over-quarter to $50.2M.

Based on Healthcare Value Capital's 13F filing for Q2 2021, filed 16 Aug 2021.